Leuzzi Vincenzo, Mastrangelo Mario, Polizzi Agata, Artiola Cristiana, van Kuilenburg André B P, Carducci Carla, Ruggieri Martino, Barone Rita, Tavazzi Barbara, Abeling Nico G G M, Zoetekouw Lida, Sofia Vito, Zappia Mario, Carducci Claudia
Division of Child Neurology, Department of Pediatrics and Child Neurology and Psychiatry, "Sapienza", University of Rome, Via dei Sabelli, 108-00141, Rome, Italy,
JIMD Rep. 2015;15:39-45. doi: 10.1007/8904_2014_295. Epub 2014 May 1.
Two sisters were diagnosed in their adulthood with aromatic L-amino acid decarboxylase (AADC) deficiency (OMIM#608643). They experienced early myasthenia-like manifestations, myoclonic jerks, oculogyric crises, tremors, and developmental delay during childhood; clinical stabilization afterwards; and spontaneous improvement during adolescence and young adulthood. Two novel pathogenic mutations on DDC gene [p.Tyr37Thrfs*5 (c.105delC) and p.F237S (c.710 T>C)] were associated with undetectable enzyme activity in plasma and only a mild reduction of biogenic amines in cerebrospinal fluid (CSF). The increase of both 3-O-methyldopa and 5-hydroxytryptophan on CSF was the most relevant biochemical alteration denoting AADC defect in these subjects. Transdermal rotigotine remarkably improved their gross motor functions and the asthenic status they complained. The present cases broaden the phenotypic spectrum of AADC deficiency and suggest that (1) AADC defect is not a progressive neurological disease and behaves rather as a neurodevelopmental disorder that improves during the second decade of life; (2) treatment-naïve adults can still respond well to neurotransmitter therapy; and (3) the possibility of a mild presentation of AADC deficiency should be considered when examining young adults with asthenic and parkinsonian symptoms.
两姐妹成年后被诊断为芳香族L-氨基酸脱羧酶(AADC)缺乏症(OMIM#608643)。她们在儿童期出现早期肌无力样表现、肌阵挛性抽搐、动眼危象、震颤和发育迟缓;之后病情临床稳定;在青春期和青年期自发改善。DDC基因上的两个新的致病突变[p.Tyr37Thrfs*5(c.105delC)和p.F237S(c.710 T>C)]与血浆中无法检测到的酶活性相关,且脑脊液(CSF)中生物胺仅轻度减少。脑脊液中3-O-甲基多巴和5-羟色氨酸的增加是这些受试者中表明AADC缺陷的最相关生化改变。透皮罗替戈汀显著改善了她们的总体运动功能以及她们所抱怨的虚弱状态。本病例拓宽了AADC缺乏症的表型谱,并提示:(1)AADC缺陷不是一种进行性神经疾病,而是一种在生命第二个十年有所改善的神经发育障碍;(2)未经治疗的成年人对神经递质治疗仍可能有良好反应;(3)在检查有虚弱和帕金森症状的青年成年人时,应考虑AADC缺乏症轻度表现的可能性。